Adam Klein

Partner

International Corporate and Securities Department

Adv. Klein is a partner and Deputy Department Head of the International Corporate and Securities Department and is a member of the firm’s Executive Committee. Adv. Klein specializes in cross-border corporate and finance transactions, including mergers and acquisitions, public offerings, tender offers, ‘going private’ transactions, spin-offs, PIPEs, and private equity and venture capital investments.

Adv. Klein advises Israeli SEC-registered companies and dual-listed companies on their corporate governance requirements under Israeli law and under the rules of the SEC, NYSE, and NASDAQ. Adv. Klein also advises foreign companies and investment funds on their acquisitions, financings, investments and business activities in Israel. He possesses particular expertise in U.S. public offerings and public offerings of foreign companies on the Tel Aviv Stock Exchange.

In recent years, Adv. Klein has advised on some of the largest and most complex merger and acquisition transactions and cross-border public offerings in Israel, in which he has represented multinational corporations and private equity funds in Israeli transactions, as well as Israeli corporations in overseas transactions.

Adv. Klein has been recognized as one of Israel’s leading attorneys in the capital markets, corporate and M&A fields by Chambers & Partners and Best Lawyers.

Adv. Klein advised the Ethics Committee of the Israel Bar Association on rules of conduct for attorneys under the Sarbanes-Oxley Act; crafted the first U.S.-style Shareholder Rights Plan (‘Poison Pill’) in Israel, which enables public companies to defend themselves from hostile takeovers; and lecturers to professional audiences on a variety of legal topics.

From 1992 to 1999, Adv. Klein was an associate in the Corporate and Financial Services Department of Willkie Farr & Gallagher, New York.

Education

J.D., Columbia Law School, New York, 1991

Notes Editor, Columbia Journal of Transnational Law

B.A. (magna cum laude), English Literature, Yeshiva University, New York, 1987

Bar Admission

Israel Bar Association, 2000

New York Bar Association, 1992

"Respected in the market and highlighted by peers for his extensive experience advising clients on international matters, in particular between Israel, the USA and the UK."

Chambers & Partners | 2020

"Extremely pragmatic, with a very down-to-earth approach… understands the subtleties of securities law."

Chambers & Partners | 2019

"A skilled transactional lawyer with a particularly strong client following in the pharmaceutical and technology markets."

Chambers & Partners | 2019

"Very pragmatic, careful and analytical. He is attuned to his client's needs and is a pleasure to work with."

Chambers & Partners | 2018

"Lauded for his great business sense and knowledge of Israeli and US securities."

Chambers & Partners | 2017

Selected Transactions

Edwards Lifesciences Corporation - Valtech Cardio Ltd.
690M USD

Representing Valtech Cardio Ltd. in its acquisition by Edwards Lifesciences Corporation for up to $690 million.

PennantPark Floating Rate Capital Ltd.
488M ILS

Representing NASDAQ listed PennantPark in the issue of a debenture series and dual listing on the TASE, raising over 488M ILS.

Teva Pharmaceutical Industries Ltd.

Advising Teva's Special Litigation Committee regarding a derivative claim.

NICE Ltd.
460M USD

Representing NICE Ltd. in its $460 million bond offering to institutional investors.

Israel Chemicals Ltd.
463M USD

Representing Israel Chemicals Ltd. in its IPO on the NYSE, in which its shareholders raised $463M.

Warburg Pincus LLC - Leumi Card Ltd.
2.5B ILS

Representing Warburg Pincus LLC in its acquisition of the credit card company Leumi Card Ltd. from Bank Leumi and the Azrieli Group for approximately 2.5B ILS.